Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513233 | 0.80 | LMNA (0.42) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5412870 | 0.76 | MAPT (0.47) | LMNAMAPTCYP1A2POLBNCF1 | |
| SCHEMBL4744528 | 0.76 | LMNA (0.52) | LMNAMAPTCYP1A2POLBNCF1 | |
| SCHEMBL4748400 | 0.73 | MAPT (0.52) | LMNAMAPTCYP1A2POLBNCF1 | |
| SCHEMBL3646808 | 0.73 | LMNA (0.68) | LMNAMAPTCYP1A2POLBNCF1 | |
| SCHEMBL11088559 | 0.71 | MAPT (0.60) | LMNAMAPTCYP1A2POLBNCF1 | |
| SCHEMBL30824509 | 0.69 | MAPT (0.67) | LMNAMAPTCYP1A2NCF1L3MBTL1 | |
| SCHEMBL318704 | 0.69 | MAPT (0.67) | LMNAMAPTCYP1A2NCF1L3MBTL1 | |
| SCHEMBL10754312 | 0.69 | PARP1 (0.47) | LMNAMAPTPOLBL3MBTL1MEN1 | |
| SCHEMBL10824124 | 0.68 | LMNA (0.72) | LMNAMAPTCYP1A2POLBNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1432421-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003028726-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | LMNA 2524/4885MAPT 4336/4885CYP1A2 124/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | LMNA 2603/4885MAPT 4644/4885CYP1A2 2728/4885 |
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | LMNA 2624/4885MAPT 3523/4885CYP1A2 849/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | LMNA 2524/4885MAPT 4336/4885CYP1A2 124/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | LMNA 2424/4885MAPT 3290/4885CYP1A2 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.